Predicate |
Object |
assignee |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_8ce7e5ae3b93c05abe32afc08089aabe |
classificationCPCAdditional |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07K2317-31 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07K2317-24 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07K2317-77 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07K2317-92 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07K2317-76 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K2039-545 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K2039-507 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K2039-505 |
classificationCPCInventive |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07K16-2818 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07K16-2809 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07K16-30 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07K16-3007 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K39-3955 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P35-00 |
classificationIPCInventive |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C07K16-28 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61P35-00 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K39-395 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/G01N33-577 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C12N15-63 |
filingDate |
2017-11-03-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
inventor |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_ed6001f283d5fea21a237801c66df63c http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_f8088b5684fecd438342b9c4bb17de51 |
publicationDate |
2018-11-29-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
publicationNumber |
WO-2018217227-A1 |
titleOfInvention |
Novel anti-pd-1 checkpoint inhibitor antibodies that block binding of pd-l1 to pd-1 |
abstract |
The present invention concerns compositions and methods of use of anti-PD-1 antibodies comprising CDR sequences corresponding to SEQ ID NO:1 to SEQ ID NO:6. Preferably the antibody is a humanized antibody comprising the variable region amino acid sequences of SEQ ID NO: 9 and SEQ ID NO:10. The antibodies are of use to treat cancer and may be administered alone or with another standard anti-cancer therapy. The methods may comprise administering the anti-PD-1 antibody or antigen-binding fragment thereof in combination with one or more therapeutic agents such as antibody-drug conjugates, interferons (preferably interferon-α), and/or other checkpoint inhibitor antibodies. |
isCitedBy |
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/WO-2022261310-A1 http://rdf.ncbi.nlm.nih.gov/pubchem/patent/CN-111808190-A http://rdf.ncbi.nlm.nih.gov/pubchem/patent/WO-2022261301-A1 http://rdf.ncbi.nlm.nih.gov/pubchem/patent/WO-2023178181-A1 http://rdf.ncbi.nlm.nih.gov/pubchem/patent/WO-2023147418-A1 http://rdf.ncbi.nlm.nih.gov/pubchem/patent/WO-2023122581-A2 http://rdf.ncbi.nlm.nih.gov/pubchem/patent/WO-2023122615-A1 http://rdf.ncbi.nlm.nih.gov/pubchem/patent/WO-2023076983-A1 http://rdf.ncbi.nlm.nih.gov/pubchem/patent/WO-2021057764-A1 http://rdf.ncbi.nlm.nih.gov/pubchem/patent/EP-4245756-A1 http://rdf.ncbi.nlm.nih.gov/pubchem/patent/WO-2021025140-A1 http://rdf.ncbi.nlm.nih.gov/pubchem/patent/WO-2023077030-A1 http://rdf.ncbi.nlm.nih.gov/pubchem/patent/WO-2021006199-A1 http://rdf.ncbi.nlm.nih.gov/pubchem/patent/WO-2022135441-A1 http://rdf.ncbi.nlm.nih.gov/pubchem/patent/WO-2020238788-A1 |
priorityDate |
2017-05-24-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
type |
http://data.epo.org/linked-data/def/patent/Publication |